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Combination antiretroviral therapy
(cART) has dramatically decreased the
progression to acquired immune deficiency
syndrome (AIDS) and thus the human
immunodeficiency virus (HIV)-related
mortality in HIV-infected patients.
Consequently, hepatitis C virus (HCV)
has emerged as a leading cause of death
in HIV/HCV co-infected patients.
Pre-existing HIV infection increases the
rate of chronicity in acute HCV infection1
and is associated with higher HCV
viraemia.2 Most importantly, HIV/HCV
co-infected patients show more rapid
progression to cirrhosis and its complica-
tions.3 This particular observation is still
incompletely understood and seems to
contradict the assumptions that HCV by
itself is not cytopathic, that the level of
viraemia does not correlate with the risk
of fibrosis and cirrhosis in HIV-negative
patients and that liver inflammation is
immune mediated.
The clinical outcome of acute hepatitis
C in HIV-negative patients is associated
with a strong and maintained HCV-
specific CD4+ T-cell response against
both structural and non-structural
proteins,4 which is typically weak in
patients with chronic hepatitis C. The role
of HCV-specific CD4+ T-cell responses in
treatment-induced viral clearance has been
examined in several studies, yielding
divergent results: while some studies
found a moderate but significant increase
in the HCV-specific CD4+ T-cell response
during antiviral treatment with a peak
late in the course of treatment, other
studies have described a decrease in HCV-
specific CD4+ T-cell responses during
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interferon/ribavirin treatment.5 6 From an
immunologist’s point of view this is
remarkable because the removal of the
viral antigen alone obviously is not suffi-
cient for the recovery of T-cell function as
would be expected from various animal
models of T-cell exhaustion. An even
further impairment of HCV-specific T-cell
responses is a hallmark of HIV/HCV co-
infected patients and this is in line with
the higher rate of chronic viral persistence.
The relationship to the less favourable
course of chronic hepatitis C, however, is
less clear. HIV as well as cART interfere
with CD4+ T cells in multiple ways and
may thus influence the clinical course of
HCV infection. In the absence of a robust
small animal model, studies in humans,
like the one presented, are currently the
only way to find new pieces for this
puzzle, such as if and how cART can
restore HCV-specific immune responses
and reverse profibrotic processes.
In this issue of Gut, Rohrbach et al
analysed the T-cell response in 80 HIV/
HCV co-infected individuals before and
during efficient cART by ex vivo g-inter-
feron enzyme linked immunospot tech-
nique responses to HCV core peptides,
which predominantly stimulate CD4+ T
cells (see page 1252).7 An increase ofHCV-
specific immune responses was found both
in individuals with chronic and spontane-
ously cleared HCV infection. In addition,
a slight long-term decrease in HCV RNA
levels was shown.
What is the importance of recovering
these T-cell responses associated with a
decrease in viral load? Given the associa-
tion of strong and broad T-cell responses
with spontaneous recovery in HCV
mono-infection, reconstitution of efficient
immune responses was developed as a
therapeutic strategy to treat chronic
hepatitis C. Two recent phase I
clinical trials, one from France using
recombinant modified vaccinia ankara and
the other from Sweden employing
a desoxyribonucleic acid vaccine, provided
a proof of concept with transient declines
in viral load up to 2 log in some patients
(http://www.transgene.fr/images/stories/
en/pdf/communique_presse/communiques_
divers_2009/PR-US-23-04-2009-TG4040-
HCV.pdf and http://feed.ne.cision.com/
wpyfs/00/00/00/00/00/10/1B/0C/wkr0011.
pdf, both accessed 23 June 2010). Impor-
tantly, the decrease in viral load was asso-
ciated again with a transient induction of
HCV-specific T-cell responses. From this
point of view it is exciting that an obvious
change in HCV-specific T-cell responsive-
ness could also be seen during cARTof HIV/
HCV co-infection. This is remarkable since
it is believed that antigen removal is
a requirement for reconstitution of func-
tional antiviral T-cell responses.8 It is
tempting to speculate that in the upcoming
era of HCV-specific protease and poly-
merase inhibitors another step of recovering
dysfunctional T cells might be achieved.
It is unclear to what extent HCV-
specific T-cell responses insufficient to
completely clear HCV contribute to liver
damage in chronic persistent hepatitis. In
view of the data from Rohrbach et al also
a protective role of certain T-cell responses
can be conceived. For example, Th2-type
CD4+ T-cell responses have been found to
be relevant for development of fibrosis in
one model.9 This process can potentially
be counteracted by g-interferon, which in
addition to its antiviral effect has anti-
fibrotic properties. The relative lack of
virus-specific g-interferon production as
found inHIV/HCV co-infectionmight thus
be related to disease pathogenesis.10 11
Indeed, several studies examining the
impact of cARTon liver diseasemorbidity in
HIV/HCV co-infection have generally
found a protective effect on fibrosis
progression.12 The finding of increased
production of g-interferon might be an
explanation for this observation.
A slight but significant decrease in HCV
RNA levels was particularly evident in the
subgroup of individuals with increasing
HCV-specific immune responses. Similar
findings and correlations between higher
CD4+ T-cell counts and preserved
immunity exhibiting lower levels of HCV
viraemia have been described before.13 The
presented data therefore provide further
support for the concept that restoration of
HCV-specific T cells may result in
improved control of HCV viraemia in
HIV/HCV co-infected patients. It remains
open, however, whether the clinical
benefit is mediated by the decreased level
of viraemia or by otherdfor example,
antifibrotic, effects of the improved HCV-
specific CD4+ T-cell response.
In summary the lessons that can be
learnt from interaction of cART in HIV/
HCV co-infection and the resulting
changes in the cellular immune response
give interesting new insights into the
mechanisms associated with viral load and
liver disease progression. The study by
Rohrbach et al provides some evidence
that the benefits for HCV disease of an
effective treatment for HIV could occur in
part through restoration of HCV-specific
immune responses. Given their overall
significance also in HCV mono-infection,
a detailed phenotypical and functional
analysis of the T-cell response during
cART appears to be the next important
step in defining surrogate markers of
a favourable course of HIV/HCV co-
infection. Growing evidence of the bene-
ficial effects of cART in preventing adverse
liver-related outcomes in HCV co-infected
patients and increasing knowledge about
the underlying mechanisms should be
taken into account when treatment
strategies of co-infected patients are
discussed.
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